Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taro Pharmaceutical Industries has received final approval from the FDA for its abbreviated new drug application for lamotrigine tablets, 5mg and 25mg.
Subscribe to our email newsletter
Lamotrigine chewable tablets, marketed by GlaxoSmithKline as Lamictal chewable dispersible tablets, is a prescription pharmaceutical product used in treating seizures.
Taro previously filed a ‘Paragraph IV’ certification challenging GlaxoSmithKline’s patent protection on Lamictal.